YHLO
- Company typePublic
- Founded2008
- HeadquartersShenzhen, China
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
YHLO firmographics
Firmographics- Name
- YHLO
- Legal name
- Shenzhen YHLO Biotech Co., Ltd.
- Website
- https://en.szyhlo.com
- Company type
- Public
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
YHLO industry classification
Industry- Product category
- In-Vitro Diagnostics (IVD) Instruments and Reagents
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Clinical Chemistry & Immunoassay Systems (HLAHAAAA)
- akta.pro secondary industries
- Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Sample Logistics, Biorepository & IVD Kit Management (Trial Support) (HLAGAEAI)
Keywords
Where YHLO is headquartered
LocationHeadquarters
- HQ city
- Shenzhen
- HQ country
- China
- HQ region
- Asia
Offices9 records
Markets served
YHLO business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- IVD Instruments and Analyzers: Sale of automated CLIA analyzers (iFlash 1200/1800/3000/9000), biochemistry analyzers (iBC 900), and total laboratory automation systems (iTLA mini Plus, iTLA Max). Instruments are sold directly and through distributors to hospitals, labs, and healthcare providers.
- IVD Reagents and Test Kits: Sale of reagent consumables for CLIA, biochemistry, immunoblotting, and other platforms covering autoimmune, reproductive health, infection, liver disease, diabetes, cardiac markers, tumor markers, and more. Over 300 products generate recurring reagent revenue.
- Professional Services and Technical Support: Technical support, training, and service center operations at seven overseas locations, providing installation, maintenance, and application support to global customers.
Go-to-market motion3 records
Distribution channels5 records
Marketing channels10 records
YHLO product offering
Product offeringCore offering
YHLO develops, manufactures, and distributes in-vitro diagnostic (IVD) instruments and reagents across six technology platforms: chemiluminescence immunoassay (CLIA), biochemistry, indirect immunofluorescence, immunoblotting, fluorescent immunochromatography, and colloidal gold immunochromatography. Its core instrument family includes the iFlash CLIA analyzers (iFlash 1200/1800/3000/9000), biochemistry analyzers (iBC 900), total laboratory automation systems (iTLA mini Plus, iTLA Max), and ESR analyzers. The reagent portfolio covers over 300 products for autoimmune disease, reproductive health, infection, liver disease, diabetes, cardiac markers, and tumor markers.
Product overview
YHLO is an in vitro diagnostic (IVD) company specializing in developing, manufacturing, and distributing diagnostic instruments and reagents. The core product portfolio centers on the iFlash family of chemiluminescence immunoassay (CLIA) analyzers: iFlash 9000 (high-throughput, 600 tests/hour), iFlash 3000 (300 tests/hour), iFlash 1800 (bench-top, 180 tests/hour), and iFlash 1200 (compact, 120 tests/hour). These analyzers run CLIA Test Panels covering reproductive health, autoimmunity, diabetes, infectious diseases, and routine parameters. YHLO complements the CLIA platform with laboratory automation solutions including iTLA mini Plus (compact automation with AI/machine vision) and iTLA Max (high-capacity, 1,200 samples/hour), plus iModules for modular integration. The biochemistry line includes iBC 900 analyzer. The subsidiary Drawray brand offers microfluidic products (iStar 500). Supporting platforms include Tenfly Phoenix (immunoblot), iMega Flow (flow cytometry), Vision ESR Analyzer, and Unicell (immunofluorescence). YHLO's technology bases span six platforms: chemiluminescence, biochemistry, indirect immunofluorescence, immunoblotting, fluorescent immunochromatography, and colloidal gold immunochromatography. The company also offers specialized assays like the sCD146 CLIA assay (CNS diagnostics) and the PIFI Digital Intelligence Platform for islet function assessment. The portfolio addresses diagnostics across autoimmunity, reproductive health, infection, liver disease, diabetes, cardiovascular diseases, and respiratory diseases.
Differentiator
Problem solved
Functional benefit
Brands
- Drawray: Subsidiary brand producing microfluidics products including iStar 500 (highly-automated Mono-test Analyzer) and Unicell (Immunofluorescence Reader)
- iTLA
- iFlash
- Tenfly
- iMega Flow
- Vision
Products and services
- iFlash 9000 Chemiluminescence Immunoassay Analyzer High-throughput CLIA analyzer delivering up to 600 tests/hour for demanding laboratory environments, with 2 optional sample loading units, expandable to 4 units linked with iTLA system, 40 reagent positions with onboard refrigeration, and 3000 reaction vessel capacity.
- iFlash 3000 Chemiluminescence Immunoassay Analyzer Fully automatic CLIA analyzer with 300 tests/hour throughput for middle and large laboratories, scalable up to 4 units and seamlessly integrable with TLA systems.
- iFlash 1800 Chemiluminescence Immunoassay Analyzer Bench-top CLIA analyzer for clinical labs with up to 180 tests/hour throughput, 20 onboard reagent positions, and 50 sample positions with emergency function.
- iFlash 1200 Chemiluminescence Immunoassay Analyzer Compact CLIA workstation for low-mid volume testing laboratories with up to 120 tests/hour, 16 sample positions, 15 reagent positions, and up to 500 reaction vessels onboard.
- iTLA mini Plus Laboratory Automation System Compact total laboratory automation system integrating input, output and centrifuge modules, processing up to 600 tubes/hour per module, supporting multiple sample loading methods with AI and machine vision for intelligent sample management, connecting up to 4 biochemistry or immunology analyzers.
- iTLA Max Intelligent Total Laboratory Automation System High-capacity intelligent total laboratory automation system processing up to 1,200 samples/hour with balanced speed, integrating AI and visual recognition for comprehensive laboratory workflow automation.
- iBC 900 Fully Automatic Chemistry Analyzer High-speed fully automatic biochemistry analyzer produced at YHLO's Xiangtan manufacturing center as part of the expanded diagnostic portfolio.
- CLIA Test Panel Comprehensive test panels including reproductive health, autoimmunity, diabetes, infectious diseases and routine parameters delivered on the iFlash chemiluminescence platform.
- sCD146 CLIA Assay World's first sCD146 test for cerebrospinal fluid, approved by Guangdong Medical Products Administration, demonstrating AUC of 0.9962 for detecting blood-brain barrier damage in CNS demyelinating disease diagnostics.
- PIFI Digital Intelligence Platform Standardized Pancreatic Islet Function Index (PIFI) digital intelligence platform using big data-driven intelligent computing for islet function assessment, based on clinical data from over 10,000 Chinese cases.
- GLINE-2019-nCoV Ag COVID-19 Rapid Antigen Test Kit Colloidal gold immunoassay for rapid qualitative determination of nucleocapsid protein of SARS-CoV-2 in nasal or nasopharyngeal swab, delivering results in 15 minutes without electronic equipment; CE marked and BfArM approved.
- Vision ESR Analyzer Erythrocyte Sedimentation Rate (ESR) analyzer from YHLO's product portfolio.
- Tenfly Phoenix Immunoblot System Immunoblot system for autoimmune disease diagnostics within YHLO's Tenfly product line.
- iMega Flow Flow cytometry-based diagnostic platform for liquid chip testing from YHLO's technology portfolio.
Quantifiable outcome
- iTLA mini Plus processes up to 600 tubes/hour per module, enabling efficient multi-source, multi-batch sample processing
- +5 more outcomes
Companies that use YHLO
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
YHLO technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability7 records
Feature11 records
YHLO partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered flagship, minor and core.
- SanofiflagshipAt the 8th China International Import Expo (CIIE), YHLO and Sanofi launched the China Type 1 Diabetes Ecosystem Co-construction Alliance. YHLO contributes its diagnostic portfolio — including Adiponectin (early T2D risk prediction), autoantibody panel (GADA, IAA, IA-2A, ICA, ZnT8A for T1D detection), C-peptide and Insulin (β-cell function evaluation), and the PIFI digital intelligence platform — to enable early screening, accurate classification, and precise intervention for Type 1 diabetes. Sanofi contributes Tzield (teplizumab), the world's first therapy proven to delay T1D onset. This partnership integrates diagnosis with therapy for diabetes care.
- C-Mer Eye Care Holdings LimitedminorShenzhen YHLO and C-Mer jointly donated 300,000 COVID-19 Rapid Antigen Tests to Hong Kong (February 16, 2022), subsequently increased to 600,000 tests (February 22, 2022). Tests were distributed through charities to high-risk populations including elderly care workers, cleaning and security staff, and bus drivers.
- Peking UniversitycoreYHLO and Peking University established a Joint Laboratory for Molecular Diagnostics of Infectious Diseases. The collaboration focuses on R&D in liver disease diagnostics and infectious disease molecular diagnostics. The joint lab has produced multiple high-impact publications, including a study on inactivated COVID-19 vaccine booster efficacy against the Omicron variant published in Journal of Infection (IF 38.637). The partnership leverages Peking University's academic talent and YHLO's technology and commercialization capabilities.
- Institute of Biophysics, Chinese Academy of SciencescoreYHLO has established collaborative laboratories with the Institute of Biophysics of the Chinese Academy of Sciences as part of its industry-academia-research integration strategy.
- Chinese University of Hong Kong (Shenzhen)coreYHLO has established collaborative laboratories with the Chinese University of Hong Kong (Shenzhen) for joint research in IVD technology and diagnostics.
- Southern University of Science and TechnologycoreYHLO collaborates with Southern University of Science and Technology on joint research and development in the IVD field as part of its academic partnership network.
- Third People's Hospital of ShenzhencoreYHLO maintains a collaborative laboratory with Third People's Hospital of Shenzhen for clinical research and diagnostic development.
- Huazhong University of Science and TechnologycoreYHLO has an academic collaboration with Huazhong University of Science and Technology for joint research in medical diagnostics.
- National Innovation Center for High-Performance Medical DevicescoreYHLO partners with the National Innovation Center for High-Performance Medical Devices as part of China's high-performance medical device innovation ecosystem.
- Prof. Yanxi Yun (Academician)coreThe world's first sCD146 CLIA assay was developed jointly with Prof. Yanxi Yun, an academician, representing a breakthrough in precision diagnosis of CNS demyelinating diseases. The collaboration strengthens China's leadership in this diagnostic field.
- MBL (Medical & Biological Laboratories Co., Ltd.)coreMBL serves as YHLO's Japanese marketing authorization holder. YHLO's COVID-19 Rapid Antigen Test Kit was authorized by Japanese PMDA and supplied through MBL. MBL is a long-term strategic partner that has assisted in organizing YHLO Japan R&D Center events.
- JSR CorporationminorJSR Corporation is listed as a representative partner from the Japanese side at the YHLO Japan R&D Center opening ceremony.
- Beckman CoultercoreYHLO's iModules (later iTLA) modular automation system has been integrated with Beckman Coulter's Power Express clinical lab automation system. A joint installation was completed at the Sixth Hospital of Wuhan, creating a Total Laboratory Automation (TLA) solution that boosts daily workload efficiency. This cross-platform integration demonstrates YHLO's open automation architecture.
- BSI (British Standards Institution)coreBSI is YHLO's primary EU Notified Body for IVDR CE certification. YHLO has received IVDR CE certification for 200 products from BSI, including the first full Blood Bank Panel certification for a Chinese IVD company. BSI's Dr. Michael Weissig visited YHLO to present IVDR certificates. BSI is the world's first national standards institution and founding member of ISO.
Scale indicators12 records
Recent moves13 records
Expansion highlights5 records
YHLO competitors and assessment
Company assessmentDirect peers
- Tosoh Bioscience: Japanese IVD manufacturer offering the AIA-CL AIA-900/1800 chemiluminescence immunoassay analyzers. Comparable vertically-integrated CLIA model with established presence in Asian markets and a meaningful reagent menu overlap with iFlash.
- Mindray (Shenzhen Mindray Bio-Medical Electronics): Largest Chinese IVD and medical device company with a comprehensive CLIA platform (CL-series) plus BC series clinical chemistry analyzers competing directly with iFlash and iBC 900. Both share Shenzhen origin, Chinese class A hospital installed base, and global expansion via distributors into 115+ countries.
- Autobio Diagnostics: Chinese IVD manufacturer offering the AutoLumo/A2000/A6200 CLIA analyzers and matching reagent menu. Competes with YHLO across mid-tier immunoassay panels in Chinese hospitals and in emerging international markets, particularly in autoimmune and infectious disease testing.
- Maccura Biotechnology: Chinese IVD manufacturer with chemiluminescence and clinical chemistry platforms (e.g., Lumiray series) and a broad reagent menu focused on infectious disease, reproductive health, and autoimmune testing. Direct overlap with YHLO's iFlash family and reagent catalog.
- DiaSorin: Italian IVD specialist with the LIAISON XL chemiluminescence immunoassay platform and a strong specialty/specialized assay portfolio (infectious disease, autoimmune, Vitamin D). Directly comparable to YHLO in CLIA architecture and reagent specialization strategy.
- Snibe (Shenzhen New Industries Biomedical Engineering): Shenzhen-headquartered Chinese IVD company whose MAGLUMI chemiluminescence immunoassay platform is the most direct iFlash competitor globally. Both companies compete head-to-head in CLIA analyzers and reagents across autoimmune, reproductive, infectious disease, and tumor markers, and both pursue international expansion through distributors.
Broad incumbents
- Siemens Healthineers: Operator of the Atellica IM immunoassay and ADVIA Centaur platforms with an extensive installed base of TLA-ready analyzers. Direct competitive benchmark in Chinese class A hospitals and across YHLO's growing international footprint.
- Beckman Coulter Diagnostics: Provider of the DxI/Access immunoassay family and Power Express total lab automation system — the latter is integrated with YHLO's iTLA at the Sixth Hospital of Wuhan. A partner and competitor at the same time, representing both collaboration (TLA integration) and competitive pressure (own install base).
- Roche Diagnostics: Global IVD market leader with cobas e801/e601 immunoassay systems, Elecsys reagent menu, and proprietary Total Laboratory Automation (cobas connection modules). Sets the benchmark YHLO competes against on throughput, assay breadth, and lab-automation footprint in hospitals worldwide.
- Abbott Diagnostics: Global IVD incumbent offering the Alinity ci-series immunoassay/clinical chemistry analyzers and ARCHITECT i-series. Competes with iFlash/iBC 900 globally in hospital core labs and is the dominant vendor in many countries YHLO is targeting.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
YHLO social profiles
Digital presenceYHLO compliance and trust
Trust signalCompliance8 records
YHLO financial estimates
Financial estimateRevenue estimate
Valuation estimate
YHLO leadership team
Management profileNumber of profiles
Profiles5 records
YHLO subsidiaries and ownership
Company hierarchySubsidiaries3 records
YHLO funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
YHLO M&A and investment
M&A and investmentM&A
Investments3 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about YHLO
What does YHLO do?
YHLO develops, manufactures, and distributes in-vitro diagnostic (IVD) instruments and reagents across six technology platforms: chemiluminescence immunoassay (CLIA), biochemistry, indirect immunofluorescence, immunoblotting, fluorescent immunochromatography, and colloidal gold immunochromatography. Its core instrument family includes the iFlash CLIA analyzers (iFlash 1200/1800/3000/9000), biochemistry analyzers (iBC 900), total laboratory automation systems (iTLA mini Plus, iTLA Max), and ESR analyzers. The reagent portfolio covers over 300 products for autoimmune disease, reproductive health, infection, liver disease, diabetes, cardiac markers, and tumor markers.
Is YHLO a public or private company?
YHLO is a public company. It is classified as public and is currently operating.
When was YHLO founded?
YHLO was founded in 2008. It employs 51 to 100 people.
Where is YHLO based?
YHLO is headquartered in Shenzhen, China, in the Asia region.
How does YHLO make money?
Three revenue lines are on record. IVD Instruments and Analyzers are the primary driver. The others are IVD Reagents and Test Kits and professional Services and Technical Support.
Who are YHLO's main competitors?
Direct peers on record are Tosoh Bioscience, Mindray (Shenzhen Mindray Bio-Medical Electronics), Autobio Diagnostics, Maccura Biotechnology, DiaSorin and Snibe (Shenzhen New Industries Biomedical Engineering). Broad incumbents are Siemens Healthineers, Beckman Coulter Diagnostics, Roche Diagnostics and Abbott Diagnostics.
Does YHLO have an API?
No public API is recorded for YHLO.
What industry is YHLO in?
YHLO's product category is In-Vitro Diagnostics (IVD) Instruments and Reagents. Its primary akta.pro industry code is HLAHAAAA, Clinical Chemistry & Immunoassay Systems, with a secondary code of HLAAAMAL, Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls). Its NAICS code is 325413 and its SIC code is 2835.